Provided is a useful pharmaceutical composition that exhibits effects of improving sleep quality, relieving stress, and reducing fatigue feeling in a mammal (for example, a human) target by ingestion or administration of a composition containing at least one substance selected from the group consisting of citric acid and a salt thereof.

Provided is a useful pharmaceutical composition that exhibits effects of improving sleep quality, relieving stress, and reducing fatigue feeling in a mammal (for example, a human) target by ingestion or administration of a composition containing at least one substance selected from the group consisting of citric acid and a salt thereof.

Chronic pain patients complain about sleep disturbance with a high probability, while sleep loss increases pain in chronic pain patients. Sleep problems and pain promote a vicious spiral, suggesting a need for simultaneous treatment of both. The present invention provides a method to treat pain-related sleep disorders through distribution of a therapeutic amount of a KOR antagonist. The use of KOR antagonist could be a novel therapeutic agent for sleep disturbance in chronic pain patients. Additionally, KOR antagonists could be used to improve sleep in other conditions, such as depression or general anxiety disorder, where KOR signaling is induced.

Chronic pain patients complain about sleep disturbance with a high probability, while sleep loss increases pain in chronic pain patients. Sleep problems and pain promote a vicious spiral, suggesting a need for simultaneous treatment of both. The present invention provides a method to treat pain-related sleep disorders through distribution of a therapeutic amount of a KOR antagonist. The use of KOR antagonist could be a novel therapeutic agent for sleep disturbance in chronic pain patients. Additionally, KOR antagonists could be used to improve sleep in other conditions, such as depression or general anxiety disorder, where KOR signaling is induced.

The invention provides liquid compositions in the form of physically stable emulsions comprising a semifluorinated alkane. The semifluorinated alkane is comprised in the dispersed phase, which may also include an active pharmaceutical ingredient. One of the preferred active ingredients is propofol. The compositions are optionally heat sterilisable and can be used for pharmaceutical or cosmetic product applications, and administered topically, intravenously, or via other routes.

The invention relates to daridorexant: Formula (I) or drochloric acid salt; for use in a method of treatment of sleep disorders such as especially insomnias, wherein daridorexant improves daytime performance, especially reduces daytime sleepiness associated to such sleep disorder

##STR00001##

The invention relates to daridorexant: Formula (I) or drochloric acid salt; for use in a method of treatment of sleep disorders such as especially insomnias, wherein daridorexant improves daytime performance, especially reduces daytime sleepiness associated to such sleep disorder

##STR00001##

This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT.sub.2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D.sub.1/D.sub.2 receptor signaling systems, and/or the treatment of residual symptoms.

The disclosure provides a novel polymorph of Compound (I):

##STR00001##

2-((1-(2-(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one monohydrochloride dihydrate, i.e., Form (A) of Compound (I)-HCl-2H.sub.2O. Pharmaceutical compositions comprising Form (A) of Compound (I)-HCl-2H.sub.2O and related methods of treatment are also disclosed.

Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.